BiOpticROCO:6850 92 Net Margin % is -3.13% as of Dec. 2025. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, BiOptic ranks better than 71.53% on this metric.
Net margin is calculated as Net Income divided by its Revenue. BiOptic's Net Income for the
six
months ended in Dec. 2025 was NT$-4.0 Mil. BiOptic's Revenue for the
six
months ended in Dec. 2025 was NT$129.0 Mil. Therefore, BiOptic's net margin for the quarter that ended in Dec. 2025 was -3.13%.
The historical rank and industry rank for BiOptic's Net Margin % or its related term are showing as below:
ROCO:6850'
s Net Margin % Range Over the Past 10 Years
Min: -23.7 Med: 13.88 Max: 26.48
Current: 0.52
ROCO:6850's Net Margin % is ranked better than 71.53% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs ROCO:6850: 0.52
BiOptic (ROCO:6850) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BiOptic Net Margin % Related Terms
BiOptic Net Margin % Historical Data
* Premium members only.
The historical data trend for BiOptic's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, BiOptic's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's Net Margin % distribution charts can be found below:
* The bar in red indicates where BiOptic's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a Net Margin % of -3.13% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on BiOptic and its competitors. According to the industry distribution chart, BiOptic ranks #269 out of 945 companies in the Biotechnology industry, placing it in the top 28.5%.
Is BiOptic's Net Margin % too high?
BiOptic's current Net Margin % is -3.13%. Based on the distribution chart, BiOptic ranks #269 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #269 out of 945 companies for Net Margin %. This puts BiOptic in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BiOptic and its competitors. BiOptic's current Net Margin % is -3.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.89, compared to a current price of NT$34.40 — trading 23.4% below its estimated fair value. The current Net Margin % is -3.13%. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current Net Margin % is -3.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$34.40 is trading 23.4% below its estimated GF Value™ of NT$44.89.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
Net Margin %: -3.13%
GF Value™: NT$44.89 vs. price of NT$34.40 (23.4% below fair value)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score
Get the complete analysis for ROCO:6850
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
